In this study, both groups of patients were routinely treated with donepezil hydrochloride, which is a second‐generation cholinesterase inhibitor that can selectively inhibit the hydrolysis of acetylcholine in the central nervous system, increase the concentration of acetylcholine, and improve the function of the brain choline system and cognitive function of patients, and is a long‐acting symptomatic treatment drug for AD (Dubois et al., 2012; Zhang et al., 2018). The gene discussed is BCHE; the disease is Alzheimer disease.